

## What does the Cardiologist Expect from the Echocardiogram of a Transcatheter Aortic Valve Implant?

### O que o Cardiologista Espera do Ecocardiograma no Implante Transcateter da Válvula Aórtica?

Universidade Federal do Rio de Janeiro,<sup>1</sup> Rio de Janeiro, RJ; Hospital Alberto Urquiza Wanderley,<sup>2</sup> João Pessoa, PB – Brazil.



Gláucia Maria Moraes de Oliveira<sup>1</sup> 



Marcelo Antônio Cartaxo Queiroga Lopes<sup>2</sup> 

Aortic stenosis (AS) is the most common valve disease in the elderly, with an increasing prevalence. According to the Global Burden of Disease, in Brazil, the incidence of degenerative aortic valve disease has significantly increased from 53.5 patients (95% confidence interval [CI], 48.1–59.9) in 1990 to 64.4 patients (95% CI, 57.2–72.5) per 100 thousand population in 2017, with prevalence rates of 18.5% and 24.2% among men and women, respectively.<sup>1</sup>

Transcatheter aortic valve implantation (TAVI) has become a universally accepted alternative to surgical aortic valve replacement in high-risk or inoperable patients and, more recently, possibly in intermediate-risk patients. In 2008, the first TAVI was performed in Brazil, with 2,667 cases reported in the Brazilian Transcatheter Aortic Valve Implant Registry (*Registro de Implante de Bioprótese Aórtica por Cateter e Novas Tecnologias*) thus far, with success rates similar to those described in high-performing centers worldwide.<sup>2,3</sup>

Proper selection of TAVI candidates is critical to the success of the procedure. The Heart Time, which consists of clinical cardiologists, cardiovascular surgeons, interventional radiologists, anesthesiologists, and imaging specialists, is responsible for the multidisciplinary approach for selecting the best treatment for patients.<sup>4</sup>

Advanced age, history of heart surgery, heart, renal, and/or respiratory failure, and the severity of the valve pathology

dictate the choice of procedures and treatment optimization. Risk stratification is required in asymptomatic patients. The prognosis in symptomatic patients is poor in the presence of heart failure, syncope, and angina, with estimated times between the onset of symptoms and death of 2, 3, and 5 years, respectively.<sup>5-7</sup>

Multimodal imaging plays a key role in the evaluation of patients with AS. Echocardiography (ECO) is the most frequently used method for identifying patients, followed by multi-slice computed tomography (MSCT), cardiovascular magnetic resonance imaging (also known as cardiac MRI), and coronary angiography, which are used in treatment planning. MSCT is essential for evaluating the aortic valve complex and access route and for estimating the imaging projection used to release the bioprosthesis. Furthermore, aortic valve calcium scoring by MSCT and myocardial fibrosis quantification by MRI have prognostic implications. Periprocedural transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE) for short-, medium-, and long-term follow-ups are also fundamental in the systematized approach to the management of patients with AS.<sup>6,7</sup>

High-grade AS is defined as a peak aortic velocity of  $>4$  m/s, mean gradient of  $>40$  mmHg, and valve area (VA) of  $<1$  cm<sup>2</sup>. Low-flow and low-gradient AS with a reduced ejection fraction (EF) has a VA of  $<1$  cm<sup>2</sup>, mean gradient of  $<40$  mmHg, EF of  $<50\%$ , and systolic volume index (SVi) of  $\leq 35$  mL/m<sup>2</sup>. Stress ECO with dobutamine is useful for differentiating severe from pseudo-severe AS (VA of  $>1.0$  cm<sup>2</sup> with flow normalization). In this case, the presence of contractile reserve (increased systolic volume,  $>20\%$ ) is associated with good prognosis. Low-flow and low-gradient AS with a preserved EF (VA,  $<1$  cm<sup>2</sup>; mean gradient,  $<40$  mmHg; EF,  $\geq 50\%$ ; SVi,  $\leq 35$  mL/m<sup>2</sup>) is associated with small ventricles, significant left ventricle (LV) hypertrophy, systemic arterial hypertension, and advanced age. Assessing the calcium score in the aortic valve by using MSCT is useful for determining the AS severity and prognosis. Low-gradient AS with a normal flow and preserved EF

### Keywords

Aortic Valve Stenosis; Echocardiography; Tomography; Magnetic Resonance.

**Mailing Address:** Gláucia Maria Moraes de Oliveira •  
Universidade Federal do Rio de Janeiro - R. Prof. Rodolpho P. Rocco, 255 -  
Prédio do HU 8º andar - sala 6, UFRJ. CEP 21941-913, Cidade Universitária,  
RJ - Brazil.  
E-mail: glauciam@cardiol.br / glauciamoraesoliveira@gmail.com  
Article received 1/17/2020; revised 1/18/2020; accepted 1/29/2020

**DOI:** 10.5935/2318-8219.20200024

(VA,  $<1 \text{ cm}^2$ ; mean gradient,  $<40 \text{ mmHg}$ ; EF,  $\geq 50\%$ ; SVi,  $>35 \text{ mL/m}^2$ ) is considered moderate AS.<sup>6,7</sup>

The examiner's experience is essential for increasing the accuracy of the diagnostic method, with visual assessment of the valve structure and calcification and mobility of the aortic leaflets. A mobile aortic valve will unlikely be associated with severe AS, regardless of the aforementioned measurements.<sup>8</sup> Multiple windows must be used, such as the right parasternal window, to quantify the gradient in severe AS. The measurement of the dimensions of the LV outflow tract must be repeated because the aortic orifice in AS is elliptical, which may cause the underestimation of the VA on TTE. In the near future, three-dimensional ECO can improve the accuracy of this measurement, which is useful for selecting the size of the bioprosthesis. Performing TEE may provide additional information regarding the associated mitral regurgitation when planning the intervention and the detection of paravalvular lichen, with the advantage of having no radiological contrast medium required, which minimizes the occurrence of contrast-induced nephropathy.<sup>7,8</sup>

The intervention is indicated for symptomatic patients with high-gradient severe AS (mean gradient of  $\geq 40 \text{ mmHg}$  or peak velocity of  $\geq 4.0 \text{ m/s}$ , Class I and Level of Evidence B) or low-flow and low-gradient severe AS ( $<40 \text{ mmHg}$ ) with reduced EF and evidence of contractile (flow) reserve, excluding pseudo-severe AS (Class I and Level of Evidence C).<sup>7,8</sup>

Available data from randomized controlled clinical trials and large records from elderly patients with increased surgical risk show that TAVI reduces mortality, in comparison with conservative therapy (balloon valvuloplasty and medication) in extreme-risk patients.<sup>5</sup> It is neither inferior nor superior to surgery in high-<sup>9,10</sup> and intermediate-risk patients.<sup>11,12</sup>

## References

1. GDB 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* [Internet]. 2018 [cited 2020 Feb 19];392:1789-858. Available from: [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7)
2. Monteiro C, Ferrari AD, Caramori PR, Carvalho LA, Siqueira DA, Thiago L, et al. Permanent pacing after transcatheter aortic valve implantation: incidence, predictors and evolution of left ventricular function. *Arq Bras Cardiol* [Internet]. 2017 [cited 2020 Feb 19];109(6):550-9. Available from: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S0066-782X2017001500550](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2017001500550)
3. RIBAC NT. Available from: <http://www.ribacnt.com/login.jsf;jsessionid=b721ff58e1c8bed27f2921fa379a>
4. Grinberg M. Valvular heart team. *Arq Bras Cardiol* [Internet]. 2014 [cited 2020 Feb 19];103(1):e15-7. Available from: [http://www.scielo.br/pdf/abc/v103n1/pt\\_0066-782X-abc-103-01-0e15.pdf](http://www.scielo.br/pdf/abc/v103n1/pt_0066-782X-abc-103-01-0e15.pdf)
5. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. PARTNER Trial Investigators. *N Engl J Med*. 2010;363(17):1597-607.
6. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of

Patients with low-flow and low-gradient AS with reduced EF, predominantly due to increased postload, show improved LV function after intervention. In turn, if the dysfunction results from fibrosis, the patient is highly unlikely to recover. Higher rates of vascular complications, pacemaker implantation, paravalvular regurgitation with TAVI, major bleeding, acute kidney injury, and new atrial fibrillation have been observed during surgery.<sup>6,7</sup>

## Conclusion

ECO plays a key role in AS diagnosis, TAVI implantation planning, and short- and long-term follow-ups. TTE is useful in the diagnosis of AS and for evaluating the aortic valve complex, aortic valve morphology, mitral regurgitation, and left ventricular function. TEE plays a key role during the procedure, in prosthetic valve function monitoring, and in detecting complications. Stress ECO with dobutamine is useful for evaluating asymptomatic patients and differentiating severe from pseudo-severe low-flow and low-gradient AS with an EF of  $<50\%$ . Follow-up with TTE can detect mismatches between the prosthesis and the patient, structural deterioration of the bioprosthesis with significant stenosis or regurgitation, and clinical or subclinical thrombosis, among other long-term complications.<sup>7,8</sup>

New semiautomated analysis techniques for the aortic annulus have shown good accuracy as compared with MSCT and may be incorporated in TAVI implantation planning.<sup>7,8,13</sup>

## Conflict of interest

The authors have declared that they have no conflict of interest.

- the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2017;70(2):252-89.
7. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38(36):2739-91.
8. Onishi T, Sengoku K, Ichibori Y, Mizote I, Maeda K, Kuratani T, et al. The role of echocardiography in transcatheter aortic valve implantation. *Cardiovasc Diagn Ther*. 2018;8(1):3-17.
9. Badiani S, Bhattacharyya S, Lloyd G. Role of echocardiography before transcatheter aortic valve implantation (TAVI). *Curr Cardiol Rep* [Internet]. 2016 [cited 2020 Feb 19];18(4):38. doi: 10.1007/s11886-016-0715-z. Available from: <https://link.springer.com/article/10.1007/s11886-016-0715-z>
10. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al.; PARTNER 1 Trial Investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet*. 2015;385(9986):2477-84.
11. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al.; SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N Engl J Med*. 2017;376(14):1321-31.
12. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P; Rating Panel Members & Appropriate Use Criterial Task Force. ACC/AATS/AHA/ASE/

---

ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease. *J Nucl Cardiol* [Internet]. 2019 [cited 2020 Feb 19];26(4):1392-1413. Available from: <https://link.springer.com/article/10.1007/s12350-019-01751-7>

13. Mediratta A, Addetia K, Medvedofsky D, Schneider RJ, Kruse E, Shah AP, et al. 3D echocardiographic analysis of aortic annulus for transcatheter aortic valve replacement using novel aortic valve quantification software: Comparison with computed tomography. *Echocardiography*. 2017;34(5):690-9.